Robert C. Moellering

TL;DR: RP 59500, a mixture of two semisynthetic streptogramin antibiotics, is one of a few investigational agents currently in clinical trials with inhibitory activity against multiple-drug-resistant strains of Enterococcus faecium and it is expected that bactericidal activity of this antimicrobial against the multiple- drug-resistant E. faecum strains currently encountered would be distinctly uncommon.

TL;DR: Despite the concerted efforts of modern medicine, infections due to gram-positive bacteria, such as skin and soft tissue infections, pneumonia, bacteremia, and endocarditis, continue to pose many challenges to achieving successful treatment outcomes, including the emergence and spread of methicillin resistance in Staphylococcus aureus.

TL;DR: The results suggest that the commonly used 500 mg dose of vancomycin given preoperatively may provide serum concentrations during cardiopulmonary bypass which are not bactericidal for many S. epidermidis strains, but a higher initial dose should be given.

TL;DR: The comparative in vitro activity of SM7338 was tested against 670 routine clinical isolates and 130 cefoperazone-resistant isolates of bacteria by agar dilution methods and found it to be at least as active as imipenem against gram-negative organisms but was slightly less active against Gram-positive organisms.

TL;DR: The activity of BMY-28100, a new orally administered cephalosporin, was compared with those of cephalexin and cefaclor and the drug was active against Haemophilus influenzae and gonococci but not against other organisms generally resistant to cephem antibiotics.